| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f51d5a5cf2180ceb757415957040fcc6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e7e44902ef192a85843c23323e98ec9a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e6621c0023d21f2778c4f79b5e633e42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_753d445ac5912812cf9c3ff32ad06b29
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6e67fd53503fd7709ab8dcf289260d3f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5dfc0b033ac4c841466d97a5f28ea32b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7dab98ac57b6a96b40dd7c1fe8d09051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5b295dbabf8626513403d867f5d54dad |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2010-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3d83e988a5c5f6e4ac3eb7c815d4917c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1bad04bb596cf6ca7a35f4f4d1bb8b1a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a171f8b6b4bdc51d139ad647e4afd03a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b29a73bd829d8063f5a4f68eb9254ab8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f9e7ec710c42bbc6a2eb96f06c1f95b4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5794bdef1824923732683e78a9eb914e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c74ea122544e5956a9b39b52b314a50 |
| publicationDate |
2011-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2011027800-A1 |
| titleOfInvention |
Use of biomarker(s) to identify a wee1 inhibitor responsive patient and methods of treating cancer mediated by dysfunctional or aberrant p53 via administration of a wee1 inhibitor |
| abstract |
The present invention provides the identification of biomarker gene sets whose expression levels are useful for predicting a patient's response to a therapeutically effective dose of a Wee1 inhibitor as well the ability to predict said response prior to dosing with the Wee1 inhibitor. Additional uses are also disclosed in the specification. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017095479-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015183776-A1 |
| priorityDate |
2009-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |